Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Mplusm Consulting LLC

Neither a doctor nor a teaching hospital

Research payments

$21,843,319

1,083 payments

Through program year 2025, Mplusm Consulting LLC is reported as receiving $21,843,319 in research payments, across 1,083 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $5,950,253 364
2024 Research $3,445,978 290
2023 Research $1,934,204 188
2022 Research $2,312,146 47
2021 Research $6,204,260 101
2020 Research $1,764,586 51
2019 Research $231,892 42

Breakdown

Who paid Research payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $7,816,304 181 payments
  2. Currax Pharmaceuticals LLC $5,129,864 371 payments
  3. Pfizer Inc. $2,388,280 46 payments
  4. Chiesi USA, Inc. $2,244,456 189 payments
  5. E.R. Squibb & Sons, L.L.C. $1,903,399 12 payments
  6. AstraZeneca Pharmaceuticals LP $784,114 16 payments
  7. Teva Pharmaceuticals USA, Inc. $567,638 92 payments
  8. Novavax Inc $293,633 68 payments
  9. Exact Sciences Corporation $233,963 20 payments
  10. Allergan Inc. $183,045 33 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 $4,656,787 49 payments
  2. NB (Contrave) Cardiovascular Outcomes Trial $3,966,549 252 payments
  3. A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 $2,453,979 49 payments
  4. A Phase 23 Randomized Doubleblind Doubledummy Placebo Controlled Study to Evaluate the Safety and Efficacy of 2 Regimens of Orally Administered PF 07321332Ritonavir in Preventing Symptomatic Sarscov2 Infection in Adult Household Contacts of An Individual With Symptomatic Covid19 $1,550,746 16 payments
  5. A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) $1,254,370 97 payments
  6. NB (Contrave) Cardiovascular Outcomes Trial $1,163,315 119 payments
  7. A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (Triton) $921,493 70 payments
  8. A Phase 3, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease Dementia $696,759 4 payments
  9. Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects with Psychosis Associated with Alzheimers Disease Dementia $686,644 5 payments
  10. A Phase 2 Study to Assess the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Outpatients With SARS-CoV-2 Infection $611,516 11 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record